Editorial Koshiaris
The biggest opportunity to detect myeloma is to investigate patients with symptoms once they present in healthcare services. Primary care plays one of the most important roles for the early diagnosis of myeloma as it is usually the first point of contact between the patient and the healthcare system. General practitioners (family doctors) are responsible for decisions regarding referral to secondary care. Prompt suspicion of the disease can result in more timely referrals to the appropriate departments and thus reduce time to diagnosis. Interventions implemented at the primary care level can be quite effective for early diagnosis of myeloma.
In most cancers, symptoms can be quite indicative of the diseases, for example, rectal bleeding and colorectal cancer or hematuria and bladder cancer. These types of symptoms, which are also referred to as 'red flags' in most cases, result in urgent investigation and referral to specialist services. Unfortunately, myeloma symptoms on their own are not very useful due to how common they are. Most myeloma symptoms are not predictive, with most of them having a positive predictive value of less than 1% [15] . They become more predictive when combined with abnormalities detected in blood tests such as the full blood count, creatinine, calcium and inflammatory markers [15] . Blood test combinations can be quite indicative of myeloma and different testing strategies can be used in order to rule in or rule out myeloma. A recent study has shown that certain test combinations like the erythrocyte sedimentation rate and hemoglobin can be used to rule out myeloma if found normal in patients presenting with myeloma-related symptoms, such as bone pain; abnormalities in these tests should result in more specialist investigations [16] . Given the importance of blood tests in myeloma, it is important that clinicians should have easy access to common blood tests.
Another alternative approach that could be used is the development of tools that can help clinicians flag high-risk patients for myeloma. These tools usually take the form of clinical prediction rules. In the last decade, there has been a big increase in the development of prediction rules that can be used to diagnose cancer [17] . This was made possible only recently due to the rise of electronic health record databases, which allow for the development of prediction rules in adequately powered samples, as well as the increase in computational power, which allows the analysis of such big databases [18] . Prediction rules can be used to estimate the risk of a patient based on their clinical presentation and have the potential to be automated within software systems in order to flag-up high-risk patients. Electronic trigger-based interventions have been shown to significantly reduce time to diagnosis in other cancers such as colorectal and prostate [19] . Given that, in many countries, patient information is integrated within information and software systems; this approach has the potential to become a very useful and efficient tool for the early diagnosis of cancer.
Conclusion & recommendations for future research
Some progress has been made in recent years on early diagnosis of myeloma, but there is still plenty of room for improvement. Based on current evidence, the best way to currently identify high-risk patients is through the appropriate use of common blood tests like the full blood count, inflammatory markers and calcium. Given that the incidence rate has been increasing, it is very important that more research is done on early diagnosis of myeloma [20] . Prediction rules using electronic health records data from primary care could prove to be a strong additional support tool for clinicians to identify myeloma. Future research should focus on their development, validation and implementation. Oxford CLAHRC. The views expressed are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
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